J. Atkins

3.2k citations

19 papers · 2.3k indexed · 1 hit paper · h-index 12

Impact in

Urology top 1%
- Urinary Bladder and Prostate Research
Pulmonary and Respiratory Medicine top 2%
- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment

Papers in

Oncology 9
- Colorectal Cancer Treatments and Studies 5
- Lung Cancer Research Studies 3
- Cancer Treatment and Pharmacology 2
- Pancreatic and Hepatic Oncology Research 2
Cancer Research 3

Co-authors: M. Scott Lucia Scott M. Lippman John Edwards Connie M. Szczepanek Charles A. Coltman Catherine M. Tangen Leslie G. Ford Phyllis J. Goodman
Journals: Journal of Clinical Oncology (6 papers)Annals of Oncology (6 papers)International Journal of Radiation Oncology*Biology*Physics (1 paper)British Journal of Cancer (1 paper)Breast Cancer Research and Treatment (1 paper)
Partner nations: United States Canada Poland

In The Last Decade

J. Atkins

18 papers receiving 2.2k citations

Hit Papers

align trajectories log scale

The Influence of Finasteride on the Development of Prostate Cancer 2003 · 1.7k citations

Peers

Countries citing papers authored by J. Atkins

Since Specialization

Citations

This map shows the geographic impact of J. Atkins's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Atkins with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Atkins more than expected).

Fields of papers citing papers by J. Atkins

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Atkins. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Atkins. The network helps show where J. Atkins may publish in the future.

Co-authorship network

The 25 scholars most cited alongside J. Atkins, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with J. Atkins Line = papers co-authored together J. Atkins links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

#	Work
1	Portosystemic Hepatic Encephalopathy Scores (PHES) differ between Danish and German healthy populations despite their geographical and cultural similarities Metabolic Brain Disease ·Mette Munk Lauridsen, Lea Ladegaard Grønkjær, J. Atkins, Stine Ulrik Mikkelsen, 昭夫五十嵐, Nina Kimer, Hartmut Hecker, Gabriele Berg‐Beckhoff, Karin Weißenborn, Hendrik Vilstrup	2024	1
2	A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer Annals of Oncology ·G. Deplanque, Martin Demarchi, Mohamed Hebbar, Patrick J. Flynn, Bohuslav Melichar, J. Atkins, Elżbieta Nowara, Lem Moyé, David Piquemal, M Zare Ebrahimabad, Patrice Dubreuil, Colin D. Mansfield, M. Flad, Alain Moussy, Olivier Hermine, Pascal Hammel	2015	78
3	5BA Prospective trial of endocrine therapy alone in patients with estrogen-receptor positive, HER2-negative, node-negative breast cancer: Results of the TAILORx low risk registry European Journal of Cancer ·麻里小川, R Gray, 万理伊久, Н. Рунина, K. Pritchard, Kathy S. Albain, D. F. Hayes, CE Geyer, A. Palmer, 陈平周, Maccon Keane, Carlos Vallejos, Timothy F. Goggins, Viktoriya Dergal, Adam Brufsky, D. Toppmeyer, VG Kaklamani, J. Atkins, Jessica Olson, G. W. Sledge	2015	1
4	CALGB/SWOG 80405: Phase III Trial of Irinotecan/5-FU/Leucovorin (FOLFIRI) or Oxaliplatin/5-FU/Leucovorin (MFOLFOX6) with Bevacizumab (BV) or Cetuximab (CET) for Patients (PTS) with KRAS Wild-Type (WT) Untreated Metastatic Adenocarcinoma of the Colon Annals of Oncology ·Alan P. Venook, Donna Niedzwiecki, Heinz‐Josef Lenz, Federico Innocenti, M. R. Mahoney, Bert H. O’Neil, Jawaid Shaw, Blasé N. Polite, Howard S. Höchster, J. Atkins, Richard M. Goldberg, Robert J. Mayer, Richard L. Schilsky, Monica M. Bertagnolli, Charles D. Blanke	2014	24
5	Calgb/Swog 80405: Analysis of Patients Undergoing Surgery As Part of Treatment Strategy Annals of Oncology ·Alan P. Venook, Donna Niedzwiecki, Heinz‐Josef Lenz, M. R. Mahoney, F. Innocenti, Bert H. O’Neil, Howard S. Höchster, R. M. Goldberg, Richard L. Schilsky, Robert J. Mayer, Blasé N. Polite, J. Atkins, James E. Shaw, Monica M. Bertagnolli, Charles D. Blanke	2014	16
6	Calgb/Swog 80405: Phase III Trial of Irinotecan/5-Fu/Leucovorin (Folfiri) or Oxaliplatin/5-Fu/Leucovorin (Mfolfox6) with Bevacizumab (Bv) or Cetuximab (Cet) for Patients (Pts) with Expanded Ras Analyses Untreated Metastatic Adenocarcinoma of the Colon Or Rectum (Mcrc) Annals of Oncology ·Heinz‐Josef Lenz, Donna Niedzwiecki, Federico Innocenti, Charles D. Blanke, Rachel M. Jarrold, Bert H. O’Neil, James E. Shaw, Blasé N. Polite, Howard S. Höchster, J. Atkins, Richard M. Goldberg, Robert J. Mayer, Richard L. Schilsky, Monica M. Bertagnolli, Alan P. Venook	2014	83
7	Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy Annals of Oncology ·Razelle Kurzrock, J. Atkins, Jennifer J. Wheler, Siqing Fu, Aung Naing, NL Busaidy, David S. Hong, Steven I. Sherman	2013	30
8	Elung: A Multicenter, Randomized Phase IIB Trial of “Standard” Platinum Doublets Plus Cetuximab (CET) as First-Line Treatment of Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC) Annals of Oncology ·L. Schwartzberg, Kurt W. Tauer, J. Atkins, Mokgadi Rebecca Senyolo, Felix Pfeiffle, Bruno R. Bastos, Corey J. Langer, Mark A. Socinski, David R. Spigel	2012	2
9	Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer British Journal of Cancer ·Silvia Novello, Giorgio V. Scagliotti, Rafael Rosell, Mark A. Socinski, Julie R. Brahmer, J. Atkins, Cinta Pallarés, Ateeq Ahmed H, L. Tye, Paulina Selaru, Xin-gong Wang, Richard C. Chao, Ramaswamy Govindan	2009	110
10	The impact of sharing results of a randomized breast cancer clinical trial with study participants Breast Cancer Research and Treatment ·Ann H. Partridge, Antonio C. Wolff, P. Kelly Marcom, Peter A. Kaufman, L. Zhang, Rebecca Gelman, Caroline M. Moore, Diana Lake, Gini F. Fleming, Hope S. Rugo, J. Atkins, Ebonie Sampson, Deborah Collyar, Eric P. Winer	2008	22
11	Phase III study of gemcitabine [G] plus cetuximab [C] versus gemcitabine in patients [pts] with locally advanced or metastatic pancreatic adenocarcinoma [PC]: SWOG S0205 study Journal of Clinical Oncology ·P. A. Philip, Jacqueline Benedetti, Cecilia M. Fenoglio‐Preiser, Mark M. Zalupski, Heinz‐Josef Lenz, Eileen M. O’Reilly, Risa Liang Wong, J. Atkins, Shin-Hsu Chang, Charles D. Blanke	2007	140
12	The study of tamoxifen and raloxifene (STAR): Initial findings from the NSABP P-2 breast cancer prevention study Journal of Clinical Oncology ·D. Lawrence Wickerham, Joseph P. Costantino, Victor G. Vogel, Walter M. Cronin, Reena S. Cecchini, J. Atkins, Frederic Schiller Cozzens, Louis Fehrenbacher, Worta McCaskill‐Stevens, Norman Wolmark	2006	16
13	Chemotherapy-naïve cancer patients’ expectations of developing treatment-related side effects: A URCC CCOP study of 670 patients from community practices Journal of Clinical Oncology ·M. Hofman, Gary R. Morrow, J. Mordecai, Pascal Jean‐Pierre, Shaker R. Dakhil, Timothy D. Moore, J. Atkins	2006	0
14	Phase I study pilot arms of radiotherapy and carmustine with temozolomide for anaplastic astrocytoma (Radiation Therapy Oncology Group 9813): implications for studies testing initial treatment of brain tumors International Journal of Radiation OncologyBiologyPhysics ·Susan M. Chang, Wendy Seiferheld, Walter J. Curran, Shreeram Marathe, J. Atkins, Ali Choucair, John J. Kresl, Louisa Thoron, Gregory Cairncross, Mark R. Gilbert, Jean-Paul Bahary, Carol A. Dolinskas, David N. Louis, Peter Bushunow, Jan C. Buckner, Geoffrey Barger, Minesh P. Mehta	2004	17
15	Phase II study of carboplatin, irinotecan, and thalidomide in patients with advanced non-small cell lung cancer (NSCLC) Journal of Clinical Oncology ·啓敏三竹, David B. Case, J. Atkins, Jeffrey K. Giguere	2004	5
16	Are cancer patients utilizing complementary therapies? A URCC CCOP study Journal of Clinical Oncology ·Alan Ramiro, Gary R. Morrow, Karen M. Mustian, M. Hofman, Peter Bushunow, Patrick J. Flynn, Richard J. Rosenbluth, J. Atkins	2004	1
17	Are cancer patients utilizing complementary therapies? A URCC CCOP study Journal of Clinical Oncology ·Alan Ramiro, 晃村上, Karen M. Mustian, M. Hofman, Peter Bushunow, Patrick J. Flynn, Richard J. Rosenbluth, J. Atkins	2004	1
18	The Influence of Finasteride on the Development of Prostate Cancer New England Journal of Medicine ·Ian M. Thompson, Phyllis J. Goodman, Catherine M. Tangen, M. Scott Lucia, (unknown), Leslie G. Ford, (unknown), (unknown), J. Atkins, Scott M. Lippman, Suraj V. Gaikwad, (unknown), Connie M. Szczepanek, John Edwards, Charles A. Coltman Hit paper breakdown →	2003	1749
19	Effects of Iron Treatment of Anemia in a Tropical Area American Journal of Clinical Nutrition ·Radhika Rajesh Jha, Thomas Reuter, null Winder, Shannon J. Morales, J. Atkins, 汤奇, D.M. Hegsted	1957	13

About J. Atkins

J. Atkins is a scholar working on Oncology, Cancer Research, Pulmonary and Respiratory Medicine, Hepatology and Statistics and Probability, having authored 19 papers that have together received 2.3k indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (5 papers), Lung Cancer Research Studies (3 papers), Lung Cancer Treatments and Mutations (3 papers), Neuroendocrine Tumor Research Advances (2 papers), Cancer Treatment and Pharmacology (2 papers), Pancreatic and Hepatic Oncology Research (2 papers), Cancer therapeutics and mechanisms (2 papers) and Estrogen and related hormone effects (2 papers). The work is most often cited by research in Urology (349 citations), Pulmonary and Respiratory Medicine (1.4k citations), Endocrinology, Diabetes and Metabolism (472 citations), Cancer Research (397 citations) and Oncology (625 citations). J. Atkins has collaborated with scholars based in United States, Canada and Poland. Frequent co-authors include M. Scott Lucia, Scott M. Lippman, John Edwards, Connie M. Szczepanek, Charles A. Coltman, Catherine M. Tangen, Leslie G. Ford, Phyllis J. Goodman, Ian M. Thompson and Heinz‐Josef Lenz. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, International Journal of Radiation Oncology*Biology*Physics, British Journal of Cancer and Breast Cancer Research and Treatment.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact